Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Escitalopram for GAD in HIV Patients
NCT00887679Phase 3Completed
- Sponsor
- Duke University
- Start
- May 2009
- Primary completion
- Sep 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of Escitalopram oxalate oral solution in generalized anxiety disorder (GAD), sponsored by Duke University. Primary endpoints: Hamilton Anxiety Rating Scale at 7 weeks and Beck Depression Inventory at 7 weeks. Started May 2009; status: completed.
02
Drugs
Escitalopram oxalate oral solution
03
Conditions
generalized anxiety disorder (GAD)
Beyond the preview
Go deeper on NCT00887679.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00887679.